RESUMO
Somatic versus Germline-A Case Series of Three Children with ATM- mutated Medulloblastoma.
Assuntos
Neoplasias Cerebelares , Meduloblastoma , Criança , Humanos , Meduloblastoma/diagnóstico , Meduloblastoma/genética , Meduloblastoma/terapia , Mutação em Linhagem Germinativa/genética , Neoplasias Cerebelares/diagnóstico , Neoplasias Cerebelares/genética , Proteínas Mutadas de Ataxia Telangiectasia/genéticaRESUMO
Constitutional heterozygous pathogenic variants in genes coding for some components of the Fanconi anemia-BRCA signaling pathway, which repairs DNA interstrand crosslinks, represent risk factors for common cancers, including breast, ovarian, pancreatic and prostate cancer. A high cancer risk is also a main clinical feature in patients with Fanconi anemia (FA), a rare condition characterized by bone marrow failure, endocrine and physical abnormalities. The mainly recessive condition is caused by germline pathogenic variants in one of 21 FA-BRCA pathway genes. Among patients with FA, the highest cancer risks are observed in patients with biallelic pathogenic variants in BRCA2 or PALB2. These patients develop a range of embryonal tumors and leukemia during the first decade of life, however, little is known about specific clinical, genetic and pathologic features or toxicities. Here, we present genetic, clinical, pathological and treatment characteristics observed in an international cohort of eight patients with FA due to biallelic BRCA2 pathogenic variants and medulloblastoma (MB), an embryonal tumor of the cerebellum. Median age at MB diagnosis was 32.5 months (range 7-58 months). All patients with available data had sonic hedgehog-MB. Six patients received chemotherapy and one patient also received proton radiation treatment. No life-threatening toxicities were documented. Prognosis was poor and all patients died shortly after MB diagnosis (median survival time 4.5 months, range 0-21 months) due to MB or other neoplasms. In conclusion, MB in patients with biallelic BRCA2 pathogenic variants is a lethal disease. Future experimental treatments are necessary to help these patients.
Assuntos
Proteína BRCA2 , Anemia de Fanconi , Mutação em Linhagem Germinativa , Meduloblastoma , Humanos , Proteína BRCA2/genética , Meduloblastoma/genética , Meduloblastoma/mortalidade , Meduloblastoma/patologia , Meduloblastoma/terapia , Masculino , Pré-Escolar , Feminino , Lactente , Estudos de Coortes , Anemia de Fanconi/genética , Neoplasias Cerebelares/genética , Neoplasias Cerebelares/patologia , Neoplasias Cerebelares/mortalidade , AlelosRESUMO
OBJECTIVE: Brain tumors are a global problem, leading to higher cancer-related morbidity and mortality rates in children. Despite the progressive though slow advances in neuro-oncology care, research, and diagnostics in sub-Saharan Africa (SSA), the epidemiological landscape of pediatric brain tumors (PBTs) remains underestimated. This study aimed to systematically analyze the distribution of PBT types in SSA. METHODS: Ovid Medline, Global Index Medicus, African Journals Online, Google Scholar, and faculty of medicine libraries were searched for literature on PBTs in SSA published before October 29, 2022. A proportional meta-analysis was performed. RESULTS: Forty-nine studies, involving 2360 children, met the inclusion criteria for review; only 20 (40.82%) were included in the quantitative analysis. South Africa and Nigeria were the countries with the most abundant data. Glioma not otherwise specified (NOS) was the common PBT in the 4 SSA regions combined. However, medulloblastoma was more commonly reported in Southern SSA (p = 0.01) than in other regions. The prevalence and the overall pooled proportion of the 3 common PBTs was estimated at 46.27% and 0.41 (95% CI 0.32-0.50, 95% prediction interval [PI] 0.11-0.79), 25.34% and 0.18 (95% CI 0.14-0.21, 95% PI 0.06-0.40), and 12.67% and 0.12 (95% CI 0.09-0.15, 95% PI 0.04-0.29) for glioma NOS, medulloblastoma, and craniopharyngioma, respectively. Sample size moderated the estimated proportion of glioma NOS (p = 0.02). The highest proportion of craniopharyngiomas was in Western SSA, and medulloblastoma and glioma NOS in Central SSA. CONCLUSIONS: These findings provide insight into the trends of PBT types and the proportion of the top 3 most common tumors across SSA. Although statistical conclusions are difficult due to the inconsistency in the data, the study identifies critical areas for policy development and collaborations that can facilitate improved outcomes in PBTs in SSA. More accurate epidemiological studies of these tumors are needed to better understand the burden of the disease and the geographic variation in their distribution, and to raise awareness in their subsequent management.
Assuntos
Neoplasias Encefálicas , Humanos , Neoplasias Encefálicas/epidemiologia , África Subsaariana/epidemiologia , Criança , Glioma/epidemiologia , Pré-Escolar , Adolescente , Prevalência , Meduloblastoma/epidemiologia , Meduloblastoma/terapia , Craniofaringioma/epidemiologia , LactenteRESUMO
INTRODUCTION: Advances in molecular biology have led to consensus classification of medulloblastoma into four broad molecular subgroups - wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4, respectively. Traditionally, children >3 years of age, with no/minimal residual tumor (<1.5 cm2) and lack of metastasis were classified as average-risk disease with >80% long-term survival. Younger age (<3 years), large residual disease (≥1.5 cm2), and leptomeningeal metastases either alone or in combination were considered high-risk features yielding much worse 5-year survival (30-60%). This clinico-radiological risk-stratification has been refined by incorporating molecular/genetic information. Contemporary multi-modality management for non-infantile medulloblastoma entails maximal safe resection followed by risk-stratified adjuvant radio(chemo)therapy. Aggressive multi-modality management achieves good survival but is associated with substantial dose-dependent treatment-related toxicity prompting conduct of subgroup-specific prospective clinical trials. AREAS COVERED: We conducted literature search on PubMed from 1969 till 2023 to identify putative prognostic factors and risk-stratification for medulloblastoma, including molecular subgrouping. Based on previously published data, including our own institutional experience, we discuss molecular risk-stratification focusing on WNT-pathway medulloblastoma to identify candidates suitable for treatment de-intensification to strike the optimal balance between survival and quality of survivorship. EXPERT OPINION: Prospective clinical trials and emerging biological information should further refine risk-stratification in WNT-pathway medulloblastoma.
Assuntos
Neoplasias Cerebelares , Meduloblastoma , Via de Sinalização Wnt , Humanos , Meduloblastoma/terapia , Meduloblastoma/patologia , Neoplasias Cerebelares/terapia , Neoplasias Cerebelares/patologia , Neoplasias Cerebelares/genética , Criança , Pré-Escolar , Taxa de Sobrevida , Terapia Combinada , Prognóstico , Medição de Risco , Fatores Etários , Neoplasia ResidualRESUMO
Patients with brain cancers including medulloblastoma lack treatments that are effective long-term and without side effects. In this study, a multifunctional fluoropolymer-engineered iron oxide nanoparticle gene-therapeutic platform is presented to overcome these challenges. The fluoropolymers are designed and synthesized to incorporate various properties including robust anchoring moieties for efficient surface coating, cationic components to facilitate short interference RNA (siRNA) binding, and a fluorinated tail to ensure stability in serum. The blood-brain barrier (BBB) tailored system demonstrates enhanced BBB penetration, facilitates delivery of functionally active siRNA to medulloblastoma cells, and delivers a significant, almost complete block in protein expression within an in vitro extracellular acidic environment (pH 6.7) - as favored by most cancer cells. In vivo, it effectively crosses an intact BBB, provides contrast for magnetic resonance imaging (MRI), and delivers siRNA capable of slowing tumor growth without causing signs of toxicity - meaning it possesses a safe theranostic function. The pioneering methodology applied shows significant promise in the advancement of brain and tumor microenvironment-focused MRI-siRNA theranostics for the better treatment and diagnosis of medulloblastoma.
Assuntos
Barreira Hematoencefálica , Inativação Gênica , Meduloblastoma , RNA Interferente Pequeno , Meduloblastoma/genética , Meduloblastoma/metabolismo , Meduloblastoma/terapia , Barreira Hematoencefálica/metabolismo , Animais , Camundongos , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/administração & dosagem , Humanos , Modelos Animais de Doenças , Nanopartículas de Magnetita/química , Imageamento por Ressonância Magnética/métodos , Linhagem Celular Tumoral , Polímeros/química , Neoplasias Cerebelares/genética , Neoplasias Cerebelares/metabolismo , Neoplasias Cerebelares/terapiaRESUMO
Medulloblastoma is one of the most common malignant pediatric brain tumors derived from posterior fossa. The current treatment includes maximal safe surgical resection, radiotherapy, whole cranio-spinal radiation and adjuvant with chemotherapy. However, it can only limitedly prolong the survival time with severe side effects and relapse. Defining the intratumoral heterogeneity, cellular origin and identifying the interaction network within tumor microenvironment are helpful for understanding the mechanisms of medulloblastoma tumorigenesis and relapse. Due to technological limitations, the mechanisms of cellular heterogeneity and tumor origin have not been fully understood. Recently, the emergence of single-cell technology has provided a powerful tool for achieving the goal of understanding the mechanisms of tumorigenesis. Several studies have demonstrated the intratumoral heterogeneity and tumor origin for each subtype of medulloblastoma utilizing the single-cell RNA-seq, which has not been uncovered before using conventional technologies. In this review, we present an overview of the current progress in understanding of cellular heterogeneity and tumor origin of medulloblastoma and discuss novel findings in the age of single-cell technologies.
Assuntos
Neoplasias Encefálicas , Neoplasias Cerebelares , Meduloblastoma , Criança , Humanos , Meduloblastoma/genética , Meduloblastoma/terapia , Meduloblastoma/patologia , Neoplasias Cerebelares/genética , Neoplasias Cerebelares/terapia , Neoplasias Cerebelares/patologia , Recidiva Local de Neoplasia , Neoplasias Encefálicas/patologia , Recidiva , Carcinogênese , Microambiente Tumoral/genéticaRESUMO
Pediatric brain tumors are the leading cause of cancer-related deaths in children, with medulloblastoma (MB) being the most common type. A better understanding of these malignancies has led to their classification into four major molecular subgroups. This classification not only facilitates the stratification of clinical trials, but also the development of more effective therapies. Despite recent progress, approximately 30% of children diagnosed with MB experience tumor relapse. Recurrent disease in MB is often metastatic and responds poorly to current therapies. As a result, only a small subset of patients with recurrent MB survive beyond one year. Due to its dismal prognosis, novel therapeutic strategies aimed at preventing or managing recurrent disease are urgently needed. In this review, we summarize recent advances in our understanding of the molecular mechanisms behind treatment failure in MB, as well as those characterizing recurrent cases. We also propose avenues for how these findings can be used to better inform personalized medicine approaches for the treatment of newly diagnosed and recurrent MB. Lastly, we discuss the treatments currently being evaluated for MB patients, with special emphasis on those targeting MB by subgroup at diagnosis and relapse.
Assuntos
Neoplasias Cerebelares , Meduloblastoma , Recidiva Local de Neoplasia , Humanos , Meduloblastoma/patologia , Meduloblastoma/genética , Meduloblastoma/terapia , Meduloblastoma/tratamento farmacológico , Neoplasias Cerebelares/patologia , Neoplasias Cerebelares/tratamento farmacológico , Neoplasias Cerebelares/genética , Neoplasias Cerebelares/terapia , Animais , Criança , Antineoplásicos/uso terapêutico , Medicina de PrecisãoRESUMO
Medulloblastoma (MB) is a primary brain malignancy. However, updated epidemiological data and long-term outcomes are lacking.The clinical and epidemiological datasets of patients with MB in the current study were obtained from the Surveillance, Epidemiology, and End Results (SEER) databases. Joinpoint regression models were used to assess the rate of changes in the incidence, prevalence, and treatment trends in patients with MB. Cox hazard and competition risk model analyses were used to assess overall survival (OS) and cancer-specific survival (CSS).The age-adjusted incidence of MB remained relatively stable at 0.15 per 100,000 individuals in 2019. The annual percentage change (APC) of females remained stable, whereas that of males increased over time. The 20-year limited-duration prevalence of patients with MB increased significantly from 0.00016 % in 1999 to 0.00203 % in 2018. Patients aged 5-19 years accounted for 46.7 % of all age groups, and the trend for the three treatments was increased. Average annual percentage change (AAPC) for the chemotherapy group was increased in patients aged 20 + years MB [AAPC = 2.66 (95 % CI 0.93-6.31)]. Multivariate analysis revealed that OS and CSS varied significantly according to age, year of diagnosis, histology, stage, surgery, and radiotherapy. Subgroup analysis showed that chemotherapy was associated with a favorable prognosis in high-risk groups.The incidence of MB remained relatively stable, and its prevalence increased significantly. This current population-based study further identified the prognostic factors in patients with MB. Moreover, the use of chemotherapy was associated with better survival in high-risk groups.
Assuntos
Neoplasias Cerebelares , Meduloblastoma , Programa de SEER , Humanos , Meduloblastoma/mortalidade , Meduloblastoma/epidemiologia , Meduloblastoma/terapia , Feminino , Masculino , Adolescente , Criança , Pré-Escolar , Adulto Jovem , Adulto , Estudos Retrospectivos , Pessoa de Meia-Idade , Neoplasias Cerebelares/mortalidade , Neoplasias Cerebelares/epidemiologia , Neoplasias Cerebelares/terapia , Incidência , Lactente , Prevalência , IdosoRESUMO
PURPOSE: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects. EXPERIMENTAL DESIGN: GD2 expression was evaluated on primary tumor biopsies of MB children by flow cytometry. GD2 expression in MB cells was also evaluated in response to an EZH2 inhibitor (tazemetostat). In in vitro and in vivo models, GD2+ MB cells were targeted by a CAR-GD2.CD28.4-1BBζ (CAR.GD2)-T construct, including the suicide gene inducible caspase-9. RESULTS: GD2 was expressed in 82.68% of MB tumors. The SHH and G3-G4 subtypes expressed the highest levels of GD2, whereas the WNT subtype expressed the lowest. In in vitro coculture assays, CAR.GD2 T cells were able to kill GD2+ MB cells. Pretreatment with tazemetostat upregulated GD2 expression, sensitizing GD2dimMB cells to CAR.GD2 T cells cytotoxic activity. In orthotopic mouse models of MB, intravenously injected CAR.GD2 T cells significantly controlled tumor growth, prolonging the overall survival of treated mice. Moreover, the dimerizing drug AP1903 was able to cross the murine blood-brain barrier and to eliminate both blood-circulating and tumor-infiltrating CAR.GD2 T cells. CONCLUSIONS: Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.
Assuntos
Gangliosídeos , Imunoterapia Adotiva , Meduloblastoma , Receptores de Antígenos Quiméricos , Ensaios Antitumorais Modelo de Xenoenxerto , Humanos , Meduloblastoma/terapia , Meduloblastoma/imunologia , Meduloblastoma/patologia , Meduloblastoma/genética , Meduloblastoma/metabolismo , Animais , Camundongos , Gangliosídeos/metabolismo , Gangliosídeos/imunologia , Receptores de Antígenos Quiméricos/imunologia , Receptores de Antígenos Quiméricos/genética , Receptores de Antígenos Quiméricos/metabolismo , Imunoterapia Adotiva/métodos , Imunoterapia Adotiva/efeitos adversos , Linhagem Celular Tumoral , Criança , Feminino , Linfócitos T/imunologia , Linfócitos T/metabolismo , Neoplasias Cerebelares/terapia , Neoplasias Cerebelares/imunologia , Neoplasias Cerebelares/patologia , Neoplasias Cerebelares/metabolismo , Morfolinas/farmacologia , Masculino , Pré-Escolar , Benzamidas , Compostos de Bifenilo , PiridonasRESUMO
INTRODUCCIÓN: La radioterapia, quimioterapia y la cirugía empleada en el tratamiento de los tumores cerebrales tienen efectos en el eje hipotálamo-hipofisario y pueden resultar en disfunción endocrina hasta en el 96% de los casos. PACIENTES Y MÉTODO: Estudio retrospectivo y descriptivo en pacientes diagnos ticados de meduloblastoma sometidos a tratamiento con quimio y radioterapia en los últimos 20 años en un hospital terciario. Se analizan variables edad, sexo, peso, talla, índice de masa corporal (IMC) al final del seguimiento, estadio de maduración sexual, niveles séricos de TSH y T4 libre, ACTH/cortisol e IGF-1, FSH, LH, estradiol, testosterona, perfil lipídico (colesterol total) y prueba de función dinámica de hormona de crecimiento. RESULTADOS: Muestra total de 23 pacientes. El déficit de hormona de crecimiento es la secuela más frecuente (82 %) seguido de disfunción ti roidea (44,8%) y disfunción puberal (24,1%). Solo se diagnosticó un caso de diabetes insípida y 2 casos de déficit de corticotrofina. CONCLUSIONES: El seguimiento a largo plazo de los supervivientes de meduloblastoma tratados con quimio y radioterapia revela una prevalencia muy alta de disfun ción endocrina, particularmente de deficiencia de hormona del crecimiento y de hipotiroidismo. Creemos oportuna la monitorización y el seguimiento a largo plazo de estos pacientes con el fin de garantizar un manejo terapéutico adecuado de aquellas disfunciones tratables.
INTRODUCTION: Radiation therapy, chemotherapy, and surgery used to treat brain tumors have effects on the hy pothalamic-pituitary-adrenal axis and can result in endocrine dysfunction in up to 96% of cases. PATIENTS Y METHOD: Retrospective and descriptive study in patients diagnosed with medulloblasto ma who underwent treatment with chemo and radiotherapy in the last 20 years in a tertiary hospital. The variables analyzed were age, sex, weight, height, body mass index (BMI) at the end of follow-up, sexual maturity stage, serum levels of TSH and free T4, ACTH/cortisol and IGF-1, FSH, LH, estradiol, testosterone, lipid profile (total cholesterol), and growth hormone dynamic function test. RESULTS: Total sample of 23 patients. Growth hormone deficiency is the most frequent sequelae (82%) fo llowed by thyroid dysfunction (44.8%), and disorders of puberty (24.1%). Only one case of diabetes insipidus and two cases of corticotropin deficiency were diagnosed. CONCLUSIONS: Long-term follow- up of medulloblastoma survivors treated with chemo and radiotherapy reveals a very high prevalence of endocrine dysfunction, especially growth hormone deficiency and hypothyroidism. We believe that monitoring and long-term follow-up of these patients is necessary in order to ensure adequate therapeutic management of those treatable dysfunctions.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Neoplasias Cerebelares/terapia , Quimiorradioterapia/efeitos adversos , Meduloblastoma/terapia , Puberdade Precoce/etiologia , Doenças da Glândula Tireoide/etiologia , Neoplasias Cerebelares/sangue , Estudos Retrospectivos , Hormônio Adrenocorticotrópico/deficiência , Hormônio do Crescimento Humano/deficiência , Diabetes Insípido/etiologia , Doenças do Sistema Endócrino/etiologia , Sobrepeso/etiologia , Sobreviventes de Câncer , Hipogonadismo/etiologia , Meduloblastoma/sangueRESUMO
OBJECTIVES: In this study, we evaluated the association of molecular subtypes, clinical characteristics and pathological types with the prognosis of patients with medulloblastoma. METHODS: We analyzed forty patients with medulloblastoma who underwent surgical resection at our center between January 2004 and June 2014. Risk factors associated with survival, disease progression and recurrence were analyzed with a univariate Cox regression analysis, and the identified significant risk factors were further analyzed by Kaplan-Meier survival curves. RESULTS: Factors associated with overall survival included M stage (p=0.014), calcification (p=0.012), postoperative treatment, postoperative Karnofsky Performance Scale (KPS) score (p=0.015), and molecular subtype (p=0.005 for WNT and p=0.008 for SHH). Number of symptoms (p=0.029), M stage (p<0.001), and postoperative radiotherapy (p=0.033) were associated with disease progression. Patients with the WNT or SHH subtype had better survival outcomes than patients with non-WNT/SHH subtypes. Risk factors for disease progression-free survival were symptoms >2 and ≥M1 stage without postoperative radiotherapy. The risk of recurrence increased with advanced M stage. Protective factors for recurrence included M0 stage and a combination of chemotherapy and radiotherapy. CONCLUSION: We identified the risk factors associated with survival, disease progression and recurrence of medulloblastoma patients. This information is helpful for understanding the prognostic factors related to medulloblastoma.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Neoplasias Cerebelares , Meduloblastoma , Neoplasias Cerebelares/mortalidade , Neoplasias Cerebelares/patologia , Neoplasias Cerebelares/terapia , Quimioterapia Adjuvante , Terapia Combinada , Progressão da Doença , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Avaliação de Estado de Karnofsky , Meduloblastoma/mortalidade , Meduloblastoma/patologia , Meduloblastoma/terapia , Recidiva Local de Neoplasia , Período Pós-Operatório , Prognóstico , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de TempoRESUMO
OBJECTIVE: To understand the influence of play in the care process as perceived by children with cancer. METHOD: A descriptive, exploratory and qualitative study conducted in a children's cancer unit in Natal, Rio Grande do Norte, Brazil. Data were collected between October 2013 and January 2014 by means of photographic records and semi-structured interviews with eight children, and content analysis with emphasis on two categories: Auxiliary instruments during play; and The influence of play in the process of care. RESULTS: Recreational activities involve watching television, using computers, games and toys, drawing, the playroom and the clown, which provide fun, feelings of joy, distraction and interaction with other people. CONCLUSION: There are several activities at the hospital that are considered play-related and, for the children, they all benefit their care process. .
OBJETIVO: Comprender la influencia de lo lúdico en el proceso de atención, en la percepción de los niños con cáncer. MÉTODO: Estudio cualitativo, exploratorio descriptivo, realizado en un sector de oncología pediátrica en Natal, Rio Grande do Norte, Brasil. Los datos fueron recogidos entre los meses de octubre de 2013 y enero de 2014, a través de los registros fotográficos y entrevistas semiestructuradas con ocho hijos, y analizados según el análisis de contenido, destacando dos categorías de discusión: Los instrumentos auxiliares en la alegría; La influencia de lo lúdico en el proceso de atención. RESULTADOS: Las actividades recreativas implican ver televisión, usar computadoras, juegos y juguetes, la realización de dibujos y el payaso, que proporcionan diversión, sentimientos de alegría, distracción y la interacción con los demás. CONCLUSIÓN: Hay varias actividades, en el hospital, entendido como lúdico y que, para el niño, todos proporcionan beneficios para su proceso de atención. .
OBJETIVOS: Compreender a influência do lúdico para o processo de cuidar, na percepção de crianças com câncer. MÉTODO: Estudo qualitativo, exploratório descritivo, realizado em um setor de oncopediatria em Natal, Rio Grande do Norte, Brasil. Os dados foram coletados entre os meses de outubro de 2013 e janeiro de 2014, por meio de registros fotográficos e entrevista semiestruturada, com oito crianças, e analisados conforme a Análise de Conteúdo, destacando-se duas categorias de discussão: Os instrumentos auxiliares na ludicidade; e A influência do lúdico no processo de cuidar. RESULTADOS: As atividades lúdicas envolvem o assistir à televisão, o uso de computadores, os jogos e os brinquedos, a realização de desenhos, a brinquedoteca e o palhaço, os quais proporcionam diversão, sentimentos de alegria, distração e interação com outras pessoas. CONCLUSÃO: Existem diversas atividades, no hospital, entendidas como lúdicas, todas as quais, para a criança, proporcionam benefícios para o seu processo de cuidar. .
Assuntos
Humanos , Masculino , Feminino , Criança , Criança Hospitalizada/psicologia , Neoplasias/terapia , Ludoterapia , Neoplasias Cerebelares/psicologia , Neoplasias Cerebelares/terapia , Entrevistas como Assunto , Meduloblastoma/enfermagem , Meduloblastoma/psicologia , Meduloblastoma/terapia , Relações Enfermeiro-Paciente , Processo de Enfermagem , Neoplasias/enfermagem , Neoplasias/psicologia , Aceitação pelo Paciente de Cuidados de Saúde , Jogos e Brinquedos , Ludoterapia/instrumentação , Ludoterapia/métodos , Leucemia-Linfoma Linfoblástico de Células Precursoras/enfermagem , Leucemia-Linfoma Linfoblástico de Células Precursoras/psicologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Pesquisa Qualitativa , Jogos de VídeoRESUMO
Na atualidade cresce a preocupação com a neurotoxicidade do tratamento antineoplásico e o neurodesenvolvimento. O objetivo deste estudo foi comparar o impacto da modalidade de tratamento sobre a capacidade intelectiva de 22 sobreviventes de Tumores de Fossa Posterior e Leucemia Linfóide Aguda com idades entre seis e 14 anos. Participantes com astrocitoma foram submetidos à cirurgia; aqueles com meduloblastoma à cirurgia, à quimioterapia sistêmica e à radioterapia de crânio e neuroeixo (54Gy) e; aqueles com LLA à quimioterapia sistêmica e intratecal. Apenas os participantes com astrocitoma obtiveram desempenho dentro do esperado. Observou-se contrastes estatisticamente significativos entre os grupos, notadamente entre as crianças com meduloblastoma e as demais nos escores não verbais. Sugere-se que a combinação cirurgia, quimioterapia sistêmica e radioterapia potencializou as sequelas cognitivas, e reforça-se a hipótese de que a radioterapia acarreta danos à substância branca. A quimioterapia intratecal associada à sistêmica promoveu impactos significativos sobre o funcionamento executivo.
Concerns about the neurotoxicity of antineoplastic treatment and neurodevelopment are increasing nowadays. The aim of this study was to compare the impact of treatment modality on intellectual functioning of 22 survivors of Posterior Fossa Tumors and Acute Lymphoblastic Leukemia aged from six to 14 years. The astrocytoma group underwent surgery; the medulloblastoma group underwent surgery, systemic chemotherapy, and cranial and neuraxis radiation (54Gy); the LLA group underwent systemic and intrathecal chemotherapy. Only the astrocytoma group obtained average performance. Significant contrasts were obtained between groups, especially among the medulloblastoma group and others in non-verbal scores. Results suggest that the combination of surgery, radiotherapy and systemic chemotherapy increase the cognitive sequelae and enhance the hypothesis that radiation damages white matter. The association between intrathecal and systemic chemotherapy leads to significant impact on executive functioning.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Radioterapia/efeitos adversos , Astrocitoma/terapia , Cognição , Tratamento Farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Meduloblastoma/terapiaRESUMO
Com o objetivo de contribuir para a tomada de decisão do processo de gestão de tecnologias no âmbito do SUS, foi desenvolvida neste trabalho, uma avaliação de custo efetividade que compare o uso do dexrazoxano em diferentes populações e o uso do acelerador de prótons com o de fótons para tratar crianças com meduloblastoma. O horizonte temporal de toda a vida do paciente e a perspectiva de análise do SUS, foram usados em ambos os estudos. Uma análise de impacto orçamentário para cada tecnologia também foi construída. Após uma busca na literatura, foi desenvolvido um modelo de Markov capaz de comparar o uso do dexrazoxano em 6 perfis de pacientes com risco de desenvolver cardiotoxicidade. Usar o medicamento nas crianças menores de 5 anos de idade se mostrou a alternativa mais custo-efetiva (ICER de R$6.156,96), seguido de usar em todos os pacientes (ICER de R$ 58.968,7). Caso o preço diminua a um valor menor que R$250,00 por frasco, a alternativa de usar em todas as crianças se torna a mais custo-efetiva. O impacto orçamentário ao final de 5 anos foi de R$30.622.404,81 para uso apenas nas crianças menores de 5 anos. Usar a tecnologia em todas as crianças, produziria um impacto incremental de R$ 94.352.898,77. Para avaliar o custo-efetividade do acelerador de prótons, foi desenvolvido um modelo de microssimulação comparando cenários de vida útil dos equipamentos e número de pacientes tratados. Como cenário base foi adotado os parâmetros de 50 pacientes com vida útil dos equipamentos de 20 anos. Para esse cenário, o ganho em QALY foi de 2,71 e o ICER médio de R$171.012,51/QALY. Para o limiar de disposição a pagar de 1 PIB percapita foi observado que a incorporação da tecnologia seria custo-efetiva, se fosse tratar a partir de 150 pacientes. A vida útil dos equipamentos e as outras variáveis tiveram participação limitada ao serem variadas na análise de sensibilidade, sem alterar significativamente as respostas do modelo. Ao final de 20 anos, o impacto orçamentário foi de R$ 345.598.440,91. O estudo recomenda a incorporação do dexrazoxano para crianças menores de 5 anos e não recomenda a incorporação do acelerador de prótons no tratamento do meduloblastoma em crianças
Assuntos
Humanos , Criança , Criança , Análise Custo-Benefício/economia , Dexrazoxano/uso terapêutico , Efetividade , Avaliação em Saúde/economia , Meduloblastoma/terapia , Aceleradores de Partículas , Avaliação da Tecnologia Biomédica/economiaRESUMO
Medulloblastoma is the most common malignant tumors of central nervous system in the childhood. The treatment is severe, harmful and, thus, has a dismal prognosis. As PRAME is present in various cancers, including meduloblastoma, and has limited expression in normal tissues, this antigen can be an ideal vaccine target for tumor immunotherapy. In order to find a potential molecular target, we investigated PRAME expression in medulloblastoma fragments and we compare the results with the clinical features of each patient. Analysis of gene expression was performed by real-time quantitative PCR from 37 tumor samples. The Mann-Whitney test was used to analysis the relationship between gene expression and clinical characteristics. Kaplan-Meier curves were used to evaluate survival. PRAME was overexpressed in 84 percent samples. But no statistical association was found between clinical features and PRAME overexpression. Despite that PRAME gene could be a strong candidate for immunotherapy since it is highly expressed in medulloblastomas.
Meduloblastoma é o tumor maligno mais comum em sistema nervoso central na infância. O tratamento é agressivo e o prognóstico é restrito. Como PRAME está presente em vários tumores, incluindo meduloblastoma, e possui baixa expressão em tecidos normais, este antígeno pode ser ideal na imunoterapia. A fim de encontrar um potencial alvo molecular, investigamos a expressão PRAME em fragmentos de meduloblastoma e comparamos os resultados com as características clínicas de cada paciente. Análise da expressão do gene foi realizada por PCR real-time quantitativo em 37 amostras de tumor. O teste de Mann-Whitney foi utilizado para análise da relação entre a expressão do gene e características clínicas e teste de Kaplan-Meier para avaliar a sobrevida. PRAME teve superexpresssão em 84 por cento amostras, mas não houve nenhuma relação estatística entre as características clínicas e superexpressão de PRAME. Apesar disso, o gene PRAME poderia ser um forte candidato para a imunoterapia, pois é altamente expresso em meduloblastomas.
Assuntos
Criança , Humanos , Antígenos de Neoplasias/genética , Neoplasias Cerebelares/genética , Perfilação da Expressão Gênica/métodos , Meduloblastoma/genética , Proteínas de Neoplasias/genética , Neoplasias Cerebelares/terapia , Imunoterapia , Meduloblastoma/terapia , Reação em Cadeia da Polimerase/métodos , Estatísticas não ParamétricasRESUMO
OBJETIVOS: Realizar análise de sobrevida e avaliar, através de análise multivariada, a influência de diversas variáveis na sobrevida, definindo fatores prognósticos de pacientes pediátricos com tumores do sistema nervoso central (SNC) tratados em um único centro. MÉTODOS: Analisamos, retrospectivamente, a sobrevida de 103 crianças portadoras de tumores cerebrais primários, diagnosticadas consecutivamente no período entre janeiro de 2000 e dezembro de 2006. Análise multivariada de fatores influenciando a sobrevida global por regressão de Cox foi usada para definir possíveis fatores prognósticos. RESULTADOS: A mediana e a média de idade foram de 7,2 e 7,6 anos. Houve predominância do sexo masculino (relação 1,22:1). A maioria dos pacientes tinha meduloblastoma ou tumores neuroectodérmicos primitivos (PNET, 38 por cento) ou astrocitomas de baixo grau (18 por cento). As topografias mais comuns foram cerebelar (49 por cento) e tronco cerebral (21 por cento). A sobrevida, 5 anos após o diagnóstico, foi de 84 por cento para astrocitomas de baixo grau e 51 por cento para meduloblastomas e PNET. Fatores prognósticos para a sobrevida global foram histopatológico (astrocitomas de alto grau e ependimomas, razão de risco entre 3,7 e 3,9), cirurgia (razão de risco 0,5 para tumores completamente ressecados) e radioterapia (razão de risco 0,5 para pacientes que receberam radioterapia). CONCLUSÕES: A sobrevida global de pacientes pediátricos com tumores cerebrais neste estudo é comparável àquela dos registros populacionais dos Estados Unidos e Europa. Os fatores de prognóstico definidos para sobrevida global também se assemelham àqueles previamente publicados.
OBJECTIVES: To estimate survival and evaluate prognostic factors of pediatric patients with central nervous system (CNS) tumors treated in a single center. METHODS: Retrospective analysis of survival of 103 children with primary brain tumors diagnosed consecutively from January 2000 to December 2006. Cox regression was used for multivariate analysis of factors that affect overall survival to define possible prognostic factors. RESULTS: Median and mean ages were 7.2 and 7.6 years. There was a male predominance (1.22:1). Most patients had medulloblastomas or primitive neuroectodermal tumors (PNET, 38 percent), or low-grade astrocytomas (18 percent). The anatomic site of most tumors was the cerebellum (49 percent) and the brain stem (21 percent). Five-year survival after diagnosis was 84 percent for low-grade astrocytomas and 51 percent for medulloblastomas and PNET. Prognostic factors for overall survival were histopathological type (high-grade astrocytomas and ependymomas; hazard ratio = 3.7 to 3.9), surgery (hazard ratio of 0.5 for completely resected tumors) and radiotherapy (hazard ratio of 0.5 for patients who underwent radiotherapy). CONCLUSIONS: Overall survival of pediatric patients with brain tumors in this study was similar to that found in populations of the United States and Europe. The prognostic factors defined for overall survival are also similar to those published in previous studies.
Assuntos
Criança , Feminino , Humanos , Masculino , Neoplasias Encefálicas/diagnóstico , Glioma/diagnóstico , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/terapia , Brasil/epidemiologia , Métodos Epidemiológicos , Glioma/mortalidade , Glioma/terapia , Meduloblastoma/diagnóstico , Meduloblastoma/mortalidade , Meduloblastoma/terapia , Tumores Neuroectodérmicos Primitivos/diagnóstico , Tumores Neuroectodérmicos Primitivos/mortalidade , Tumores Neuroectodérmicos Primitivos/terapia , Prognóstico , Resultado do TratamentoRESUMO
En México, los tumores del sistema nervioso central representan el tercer lugar de todas las neoplasias malignas. El meduloblastoma constituye 20% de los tumores primarios del sistema nervioso central y 40% de los que se originan en el cerebelo; es el tumor maligno más frecuente en la niñez. Su origen se sitúa en la capa granular externa, normalmente migra del vermis hacia la superficie de los hemisferios cerebelosos y de ahí hacia las porciones profundas para poblar la capa granular interna de las folias. Estos tumores infiltran difusamente a través de las capas moleculares de la corteza cerebelosa por debajo de la pía, similar a lo que ocurre normalmente en las etapas embrionarias. Se diseminan por la circulación del líquido cefalorraquídeo con siembras a lo largo del espacio subaracnoideo y alrededor de la médula espinal para eventualmente salirse del sistema nervioso central y diseminarse a hueso, hígado, médula ósea y otros sitios menos frecuentes. Existen en la actualidad factores pronósticos bien definidos, así como el concepto de tratamiento multidisciplinario que ha condicionado mejores expectativas de supervivencia. El objetivo de esta revisión es actualizar el conocimiento de este tipo de tumores en nuestro país, así como los resultados terapéuticos.
In Mexico, Central Nervous System (CNS) tumors are the third most common childhood cancers. Medulloblastoma constitutes 20% of the primary CNS tumors and 40% of all cerebellar tumors, the single most common brain tumor among children. It originates over the external granular layer that normally migrates from the vermis to the surface of the cerebellum hemispheres and from there to the deep portions of the internal granular layer. These tumors infiltrate profusely the cerebellar cortex. The dissemination process can occur through the spinal fluid with seeding along the subarachnoidal space and around the spinal chord They eventually produce metastasis mainly to bone, liver, and bone marrow. There is a group of well identified prognostic factors that are relevant for each individual patient and that can be applied for multidisciplinary treatment purposes. The objective of the present review is to emphasize on new research findings and the overall survival that can be achieved with modern treatment programs.
Assuntos
Humanos , Pré-Escolar , Criança , Lactente , Meduloblastoma/terapia , Neoplasias Cerebelares/terapia , PrognósticoRESUMO
Relatamos os achados clínicos, epidemiológicos e anátomo-patológicos de 28 casos de meduloblastomas. Dos 28 pacientes analisados, 22 eram do sexo masculino e seis do sexo feminino. As idades variaram de 1 a 50 anos, com média de 15 anos. Os sinais e sintomas de maior frequência foram cefaléia (64 por cento) e vômitos (64 por cento). Em relação ao tratamento, a maioria dos pacientes foi submetida a ressecção cirúrgica total (n=10) ou a exérese parcial (n=7). Com a exceção de um paciente que apresentava meduloblastoma desmoplásico, os demais apresentavam a forma clássica do meduloblastoma. Foi evidenciada uma taxa de recidiva tumoral total de 21 por cento (n=6) em 4 anos de seguimento clínico. A quimioterapia adjuvante parece contribuir para melhor evolução clínica dos pacientes. Estes achados aproximam-se dos encontrados na literatura, contribuindo para a compreensão do comportamento biológico deste tumor.
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Neoplasias Cerebelares/epidemiologia , Meduloblastoma/epidemiologia , Distribuição por Idade , Neoplasias Cerebelares/diagnóstico , Neoplasias Cerebelares/terapia , Meduloblastoma/diagnóstico , Meduloblastoma/terapia , Recidiva Local de Neoplasia , Prognóstico , Distribuição por SexoRESUMO
Meduloblastoma, tumor maligno del SNC de origen discutido pero se admite en células neuroepiteliales germinales del techo del cuarto ventrículo. Incidencia 5,7/1.000.000 niños de 0-14 años. Corresponde a un 15-20 por ciento de todos los tumores intracraneales infantiles, más frecuentes en hombres con peak en primera década y 20-30 años. Tiene mal pronóstico con 56 por ciento sobrevida a 5 años. Objetivo: caracterizar pacientes diagnosticados de meduloblastoma en últimos 10 años. Materiales y métodos: Estudio descriptivo, observacional de prevalencia, se analizaron todos los diagnósticos histológicos de Meduloblastoma entre 1/08/95 y 31/07/05 en Patología Hospital Clínico Regional Concepción. Resulados: Nuestro universo fueron 17 pacientes con 64,7 hombres con promedio edad 17,76 años con desviación estándar de 16.82. Un 70,6 por ciento fueron pediátricos y 29,4 por ciento mayores de 15 años. Un 29,4 por ciento presentaron sólo cefalea al diagnóstico. El tratamiento fue en 88,2 por ciento cirugía total más radioterapia y quimioterapia. Desde 1995 hasta 2000 se presentaron sólo 35,29 por ciento de los casos de los últimos 10 años con promedio de edad 23,83 años y desviación estándar de 23,95 con 83,3 por ciento hombres y 16,7 por ciento mujeres. En cambio en quinquenio entre 2000 y 2005 corresponden a 64,71 por ciento de todos los casos con promedio de edad de 14,45 por ciento años y desviación estándar de 11 con 58,3 por ciento de hombres y 41,6 por ciento mujeres. Esto demuestra no sólo el aumento de casos en los últimos 5 años, sino también de aumento de casos en mujeres. En 83,3 por ciento se realizó acceso clásico suboccipital. Un 52,9 por ciento de pacientes con meduloblastoma estaba fallecido a 10 años. La sobrevida promedio de pacientes fallecidos por meduloblastoma fue de 14,22 meses con desviación estándar de 12,97.
Meduloblastoma, is a malignant tumor of the CNS of discussed origin but it is admitted in germinal neuroepiteliales cells of the ceiling of the fourth ventricle. Incidence 5,7/1.000.000 children of 0-14 years. It corresponds to a 15-20 percent of all the infantile intracraneles tumor, but it frequents in men with peak in first decade and 20-30 years. It has bad I foretell with 56 percent sobrelife to 5 years. Objective: to characterize patients diagnosed of meduloblastoma in last 10 years. Material and methods: Cross-sectional, descriptive and observational study. We analyzed all diagnose histologic of Meduloblastoma between 1/08/05 and 31/07/05 in Pathology Clinical Hospital Regional Concepciòn. Results: Our universe men with average were 17 patients with 64.7 percent age 17.76 years with s.d. 16,,82. A 70,6 percent were pediatrics and greater 29,4 percent older than15 years. A 29,4 percent presented only migraine at diagnose. Th treatment was in 88,2 percent total surgery plus radiotherapy and chemotherapy. Since 1995 up to 2000 appeared only 35.29 percent of the cases of last the 10 years from the total with 23.83 years and s.d. 23.95 83,3 percent men and 16.7 percent women. However in quinquennium between 2000 and 2005 correspond to 64.71 percent of all cases 14.45 years and d.s. 11 with 58,3 percent of men and 41,6 percent women. This demosnstrate not only a increase in cases, but also an increase in the number of women. In 83,3 percent classic access was made suboccipital. A 52,9 percent of patients with meduloblastom died to 10 years. The survival average of patients who died by Meduloblastoma was of 14.22 months with s.d. 12.97.
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Meduloblastoma/cirurgia , Meduloblastoma/diagnóstico , Meduloblastoma/mortalidade , Meduloblastoma/terapia , Sinais e Sintomas , ChileRESUMO
Os resultados de tratamento de 17 pacientes internados no Centro de Oncologia Campinas (Säo Paulo, Brasil), foram avaliados. O período de seguimento variou entre cinco e 88 meses até o levantamento dos dados. Todos os pacientes foram tratados por cirurgia e radioterapia. Houve recidiva em dois pacientes (22,5%) e a sobrevida geral foi de 94% para um ano e de 85% para cinco anos. As seqüelas neurológicas foram inexpressivas